Atanasio Pandiella

12PUBLICATIONS
34CO-AUTHORS
GlycoconjugatesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 23, 2026
Antibody-drug conjugate engineering: from design to efficacy and safety.

|Jun 25, 2026
Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer.

|Feb 27, 2026
Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies.

Mónica Redondo-Puente, María Del Carmen Gómez-García, Atanasio Pandiella

|Dec 17, 2024
Understanding the Preclinical Efficacy of Antibody-Drug Conjugates.

Cristina Díaz-Tejeiro, Alfonso López de Sá, Elisa Poyatos-Racionero

|Aug 10, 2024
Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer.

Sheila Almaraz-Postigo, Eduardo Sanz, Atanasio Pandiella

|Aug 03, 2024
Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer.

Inés Romero-Pérez, Elena Díaz-Rodríguez, Laura Sánchez-Díaz

Pageof 2

Frequent Collaborators

2 joint publications

Juan Carlos Montero

2 joint publications

Azucena Esparís-Ogando

1 joint publications

Gianluca Sala

1 joint publications

Santiago Duro-Sánchez